Literature DB >> 20922194

Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.

Margien L Seinen1, Dirk P van Asseldonk, Chris J J Mulder, Nanne K H de Boer.   

Abstract

Conventional thiopurines are considered to be effective and safe in the treatment of inflammatory bowel disease (IBD) patients; unfortunately more than 50% of patients discontinue thiopurine therapy, mainly due to the development of intractable adverse events. In recent years, the use of 6-thioguanine has been proposed as an alternative thiopurine in IBD patients failing to tolerate or to respond to conventional thiopurine therapy. In this clinical review, we describe the rationale for 6-thioguanine therapy and discuss the reported hepatotoxicity of 6-thioguanine (especially nodular regenerative hyperplasia). We propose expert-based guidelines for balanced treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922194

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  14 in total

Review 1.  Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.

Authors:  Kara Bradford; David Q Shih
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

Review 2.  Monitoring thiopurine metabolites in inflammatory bowel disease.

Authors:  Yago González-Lama; Javier P Gisbert
Journal:  Frontline Gastroenterol       Date:  2016-04-07

Review 3.  Thiopurines in inflammatory bowel disease revisited.

Authors:  Florian Bär; Christian Sina; Klaus Fellermann
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

Review 4.  Use of thiopurines in inflammatory bowel disease.

Authors:  Pascal Frei; Luc Biedermann; Ole Haagen Nielsen; Gerhard Rogler
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

Review 5.  How I treat my inflammatory bowel disease-patients with thiopurines?

Authors:  Berrie Meijer; Chris Jj Mulder; Adriaan A van Bodegraven; Nanne K H de Boer
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

Review 6.  Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review.

Authors:  Berrie Meijer; Chris Jj Mulder; Godefridus J Peters; Adriaan A van Bodegraven; Nanne Kh de Boer
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

7.  Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?

Authors:  Berrie Meijer; Margien L Seinen; Remco van Egmond; Gerd Bouma; Chris J J Mulder; Adriaan A van Bodegraven; Nanne K H de Boer
Journal:  Inflamm Bowel Dis       Date:  2017-11       Impact factor: 5.325

8.  6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities.

Authors:  Caleb D Swaim; Yi-Chieh Perng; Xu Zhao; Larissa A Canadeo; Houda H Harastani; Tamarand L Darling; Adrianus C M Boon; Deborah J Lenschow; Jon M Huibregtse
Journal:  bioRxiv       Date:  2020-07-02

9.  Noncirrhotic Portal Hypertension due to Nodular Regenerative Hyperplasia Treated with Surgical Portacaval Shunt.

Authors:  Lisa M Louwers; Jared Bortman; Alan Koffron; Veslav Stecevic; Steven Cohn; Vandad Raofi
Journal:  Case Rep Med       Date:  2012-08-21

10.  Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands.

Authors:  Floris F van den Brand; Carin M J van Nieuwkerk; Bart J Verwer; Ynto S de Boer; Nanne K H de Boer; Chris J J Mulder; Elisabeth Bloemena; Christine M Bakker; Jan M Vrolijk; Joost P H Drenth; Adriaan C I T L Tan; Frank Ter Borg; Martijn J Ter Borg; Sven J van den Hazel; Akin Inderson; Maarten E Tushuizen; Gerd Bouma
Journal:  Aliment Pharmacol Ther       Date:  2018-08-15       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.